Outcome prediction of SSTR-RADS-3A and SSTR-RADS-3B lesions in patients with neuroendocrine tumors based on 68Ga-DOTATATE PET/MR

被引:0
|
作者
Gao, Jing [1 ]
Zhou, Jinxin [1 ]
Liu, Chang [1 ]
Pan, Yu [1 ]
Lin, Xiaozhu [1 ]
Zhang, Yifan [1 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Nucl Med, 197 Ruijin 2nd Rd, Shanghai 200025, Peoples R China
基金
中国国家自然科学基金;
关键词
Neuroendocrine tumors; PET/MR; Ga-68-DOTATATE; SSTR-RADS-3A; SSTR-RADS-3B; NONMETASTATIC LYMPH-NODES; DIFFUSION-WEIGHTED MRI; BONE; CONSENSUS; DIFFERENTIATION; FEASIBILITY; METASTASES; MANAGEMENT;
D O I
10.1007/s00432-024-05776-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Somatostatin receptor (SSTR)-targeted PET imaging has emerged as a common approach to evaluating those patients with well-differentiated neuroendocrine tumors (NETs). The SSTR reporting and data system (SSTR-RADS) version 1.0 provides a means of categorizing lesions from 1 to 5 according to the likelihood of NET involvement, with SSTR-RADS-3A (soft-tissue) and SSTR-RADS-3B (bone) lesions being those suggestive of but without definitive NET involvement. The goal of the present study was to assess the ability of Ga-68-DOTATATE PET/MR imaging data to predict outcomes for indeterminate SSTR-RADS-3A and 3B lesions. Methods NET patients with indeterminate SSTR-RADS-3A or SSTR-RADS-3B lesions who underwent Ga-68-DOTATATE PET/MR imaging from April 2020 through August 2023 were retrospectively evaluated. All patients underwent follow-up through December 2023 (median, 17 months; (3-31 months)), with imaging follow-up or biopsy findings ultimately being used to classify lesions as malignant or benign. Lesion maximum standardized uptake value (SUVmax) along with minimum and mean apparent diffusion coefficient (ADCmin and ADCmean) values were measured and assessed for correlations with outcomes on follow-up. Results In total, 33 indeterminate SSTR-RADS-3 lesions from 22 patients (19 SSTR-RADS-3A and 14 SSTR-RADS-3B) were identified based upon baseline Ga-68-DOTATATE PET/MR findings. Over the course of follow-up, 16 of these lesions (48.5%) were found to exhibit true NET positivity, including 9 SSTR-RADS-3A and 7 SSTR-RADS-3B lesions. For SSTR-RADS-3A lymph nodes, a diameter larger than 0.7 cm and an ADCmin of 779 x 10(-6)mm(2)/s or lower were identified as being more likely to be associated with metastatic lesions. Significant differences in ADCmin and ADCmean were identified when comparing metastatic and non-metastatic SSTR-RADS-3B bone lesions (P < 0.05), with these parameters offering a high predictive ability (AUC = 0.94, AUC = 0.86). Conclusion Both diameter and ADCmin can aid in the accurate identification of the nature of lesions associated with SSTR-RADS-3A lymph nodes, whereas ADCmin and ADCmean values can inform the accurate interpretation of SSTR-RADS-3B bone lesions.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of 68Ga-DOTATATE in patients without neuroendocrine tumors
    H. Siebinga
    B. J. de Wit-van der Veen
    J. H. Beijnen
    M. P. M. Stokkel
    T. P. C. Dorlo
    A. D. R. Huitema
    J. J. M. A. Hendrikx
    EJNMMI Research, 11
  • [22] High degree of implementation of intended management changes after 68Ga-DOTATATE PET/CT imaging in patients with neuroendocrine tumors.
    Calais, Jeremie
    Fendler, Wolfgang
    Eiber, Matthias
    Wolin, Edward
    Slavik, Roger
    Barrio, Martin
    Gupta, Pawan
    Quon, Andrew
    Schiepers, Christiaan
    Auerbach, Martin
    Czernin, Johannes
    Herrmann, Ken
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58
  • [23] Prognostic value of volumetric parameters calculated from 68Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors
    Toriihara, Akira
    Baratto, Lucia
    Nobashi, Tomomi
    Park, Sonya
    Hatami, Negin
    Davidzon, Guido
    Kunz, Pamela
    Iagaru, Andrei
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [24] 68Ga-DOTATATE PET/CT for the Early Prediction of Response to Somatostatin Receptor-Mediated Radionuclide Therapy in Patients with Well-Differentiated Neuroendocrine Tumors
    Haug, Alexander R.
    Auernhammer, Christoph J.
    Waengler, Bjoern
    Schmidt, Gerwin P.
    Uebleis, Christopher
    Goeke, Burkhard
    Cumming, Paul
    Bartenstein, Peter
    Tiling, Reinhold
    Hacker, Marcus
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (09) : 1349 - 1360
  • [25] 68Ga-DOTATATE PET/CT for the early prediction of response to peptide receptor radionuclide therapy in patients with well differentiated neuroendocrine tumours
    Haug, Alexander
    Auernhammer, Christoph
    Waengler, Bjoern
    Schmidt, Gerwin
    Cumming, Paul
    Bartenstein, Peter
    Hacker, Marcus
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51
  • [26] Head-to-Head Comparison of SSTR Antagonist [68Ga]Ga-DATA5m-LM4 with SSTR Agonist [68Ga]Ga-DOTANOC PET/CT in Patients with Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Imaging Study
    Viswanathan, Rahul
    Ballal, Sanjana
    Yadav, Madhav P.
    Roesch, Frank
    Sheokand, Parvind
    Satapathy, Swayamjeet
    Tripathi, Madhavi
    Agarwal, Shipra
    Moon, Euy Sung
    Bal, Chandrasekhar
    PHARMACEUTICALS, 2024, 17 (03)
  • [27] Differences in tumor-to-normal organ SUV ratios measured with 68Ga-DOTATATE PET compared with 177Lu-DOTATATE SPECT in patients with neuroendocrine tumors
    Wong, Ka Kit
    Frey, Kirk A.
    Niedbala, Jeremy
    Kaza, Ravi K.
    Worden, Francis P.
    Fitzpatrick, Kellen J.
    Dewaraja, Yuni K.
    NUCLEAR MEDICINE COMMUNICATIONS, 2022, 43 (08) : 892 - 900
  • [28] The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom
    Skoura, Evangelia
    Michopoulou, Sofia
    Mohmaduvesh, Mullan
    Panagioddis, Emmanouil
    Al Harbi, Mohammed
    Toumpanakis, Christos
    Almukhailed, Omar
    Kayani, Irfan
    Syed, Rizwan
    Navalkissoor, Shaunak
    Ell, Peter J.
    Caplin, Martyn E.
    Bomanji, Jamshed
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (01) : 34 - 40
  • [29] The association between lesion tracer uptake on 68Ga-DOTATATE PET with morphological response to 177Lu-DOTATATE therapy in patients with progressive metastatic neuroendocrine tumors
    Metser, Ur
    Eshet, Yael
    Ortega, Claudia
    Veit-Haibach, Patrick
    Liu, Amy
    K. S. Wong, Rebecca
    NUCLEAR MEDICINE COMMUNICATIONS, 2022, 43 (01) : 73 - 77
  • [30] Physiologically Based Pharmacokinetic Models to Predict Organ and Tumor Distribution and Assess the Tumor Sink Effect of 68Ga-DOTATATE and 68Ga-HA-DOTATATE in Patients with Gastroenteropancreatic Neuroendocrine Tumors
    Siebinga, H.
    de Wit-van der Veen, B.
    Dorlo, T. P.
    Huitema, A. D.
    Hendrikx, J. J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S193 - S194